EFFIVAVY OF CONSERVED ELEMENT SIV GAG VACCINCE IN CONTROL OF SIVmac239 VIREMIA

保守元件 SIV GAG 疫苗控制 SIVmac239 VIREMIA 的效果

• 批准号: 8942714
• 负责人: MARK LEWIS
• 金额: $ 61.02万
• 依托单位: BIOQUAL, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2016-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8942714
• 关键词: AIDS Vaccines; AIDS vaccine development; Advanced Development; Animals; Antigens; Award; Clinical; Complement; Contracts; DNA; DNA Vaccines; Development; Elements; Epitopes; Evaluation Studies; Funding; GAG Gene; Gagging; Grant; HIV; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Macaca; Modality; Mus; National Institute of Allergy and Infectious Disease; Prevention; Prevention strategy; Research Personnel; Research Project Grants; Resources; SIV; Testing; Vaccination; Vaccine Design; Vaccine Research; Vaccines; Viremia; base; immunogenic; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; programs; prophylactic; response; vaccine candidate; vaccine evaluation

The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers. HIV sequence diversity and potential decoy epitopes are hurdles in the development of an effective AIDS vaccine. Seven conserved elements (CE) have been identified in HIV p24gag and immunogens have been generated and have shown to be immunogenic in mice and macaques.

艾滋病毒疫苗和其他预防战略的发展依赖于在临床前研究中使用非人类灵长类动物，以促进有效艾滋病疫苗候选的开发，并促进有效局部杀微生物剂和其他预防方式或基于免疫的疗法的开发。NIAID猿猴疫苗评估单位(SVEU)的合同将提供主要支持艾滋病疫苗临床前评估的非人类灵长类资源。SVEU进行研究，以支持由广泛的调查人员开发的疫苗。这些研究是对NIAID支持的基础疫苗研究和疫苗评估研究的补充，这些研究由R01(研究人员发起的研究)拨款、HIVRAD(艾滋病毒疫苗研究和设计计划)拨款、IPCAVD(临床前-临床综合艾滋病疫苗开发)拨款和NHP联盟奖项资助。SVEU还对公司或其他研究人员提供的候选疫苗进行研究。HIV序列多样性和潜在的诱饵表位是开发有效的艾滋病疫苗的障碍。已在HIV p24gag中鉴定出7个保守元件(CE)，并产生了免疫原，并已证明在小鼠和猕猴中具有免疫原性。